Our therapeutic focus
Avalyn is focused on enhancing the lives of patients by developing innovative inhaled therapies that address unmet needs in the treatment of rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs).
There are more than 200 types of interstitial lung diseases (ILDs), which are a large group of respiratory disorders characterized by inflammation, fibrosis, or both, in the lungs. Many patients with ILD manifest pulmonary fibrosis (PF), which is characterized by scarring of the lungs, which can lead to a decline in lung function, progressive shortness of breath, reduced exercise capacity and quality of life, and increased mortality risk.
Significant unmet needs persist for patients with pulmonary fibrosis. Currently, there are only two approved treatments that slow, but do not halt, disease progression. These medicines have tolerability issues that often lead to discontinuations.
IDIOPATHIC PULMONARY FIBROSIS (IPF)
- IPF is a chronic disease, characterized by progressive scarring of lung tissue
- IPF is the most well-known form of ILD. It is a rare disease affecting ~100k patients per year
- The exact cause of IPF is unknown
- Poor prognosis with a 5-year survival rate that is worse than several types of cancer
- IPF poses high disease burden that affects quality of life and reduced exercise capacity
- Only two oral medicines approved for the treatment of IPF
PROGRESSIVE PULMONARY FIBROSIS (PPF)
- PPF is a chronic disease, characterized by progressive scarring of lung tissue, leading to progressive decline in lung function, worsening symptoms, and diminished quality of life
- PPF affects ~200k patients per year in the US
- Various ILDs may lead to PPF, including but not limited to progressive autoimmune ILDs, fibrotic hypersensitivity pneumonitis, occupational and exposure related ILDs and sarcoidosis
- Only one oral medicine approved for the treatment of PPF